Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 17, 2009

DrStockPick.com Stock Report!

PWRM, NGSX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

FDA Approves NeurogesX's Qutenza After the market closed on November 16, 2009, NeurogesX (NGSX) announced that the U.S. FDA had approved Qutenza (capsaicin patch) for the management of neuropathic pain due to postherpetic neuralgia (PHN).  We expect management to spend the next several months preparing for the launch by facilitating reimbursement procedure, establishing distribution channels, hiring and training the specialty sales force, and conducting the manufacturing for commercial supply. Key to our bullish sales forecast for the drug will be establishing a permanent reimbursement code for both the product and application, as Qutenza requires administration by a physician or healthcare professional. Qutenza is a cutaneous (skin) patch designed to treat peripheral neuropathic pain conditions. The Qutenza patch provides a pure high concentration (8%) of a synthetic capsaicin, known as trans­-capsaicin, directly to the site of pain via a rapid-delivery cutaneous delivery system designed to provide ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday November 17, 2009 are:

**************************************************************

NGSX, NeurogesX, Inc.

NGSX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.

** The U.S. Food and Drug Administration (FDA) has approved NGSX’s Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia, the nerve pain which can follow an attack of shingles.

NGSX’s Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced

...

This post provides links to a number of interesting articles I have read over the past few days that you may also enjoy.

• Jennifer Hughes (Financial Times): Visibility improved but storms may lie ahead, November 13, 2008. The fog is beginning to lift. All year executives, analysts and investors have talked of a “lack of visibility” on the outlook for the economy, earnings and financial markets. By “visibility” they are in essence complaining about the uncertainty that clouds all forecasts all the time, but which we had increasingly managed to ignore during such a steady run of good times. Investors are becoming more confident that the fog is lifting, but that does not necessarily mean there is sunshine waiting just behind it.

• Doug Kass (TheStreet.com): Market ignorance is bliss, November 12, 2009. I do believe with some certainty that the market’s vulnerability

...

AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% and 10% respectively, all other segments increased their revenues. AstraZeneca recorded more than 26% of ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday November 13, 2009

DrStockPick.com Stock Report!

CEPH, PWRM

**************************************************************

CEPH, Cephalon Inc.

CEPH engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.

According to a Securities and Exchange Commission filing yesterday, CEPH will give Barr Pharmaceuticals Inc. (which now is part of Israel-based Teva Pharmaceutical Industries) a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement.

More about CEPH at www.cephalon.com

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer

...

If You Thought the Housing Meltdown Was Bad… Doug Hornig, Senior Editor, (Casey Research):

…wait until you see what’s in the cards for commercial real estate.

That’s right, the next train wreck will be in commercial real estate. Couldn’t be worse than last year’s residential market crash? That remains to be seen. But it’s coming soon, probably as early as the second quarter of next year, and there’s nothing that can prevent it. The government will intervene, trying desperately to delay the day of reckoning, and may even succeed. For a while. But make no mistake about it, that train is going off the tracks no matter what.

Every part of the sector – from multifamily apartment buildings to retail shopping centers, suburban office buildings, industrial facilities, and hotels – has accumulated a huge amount of defaulted or nonperforming paper. It’s an impossible, swaying structure that cannot long stand.

Just ask Andy Miller.

Andy

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday November 13, 2009 are:

**************************************************************

EMKR, EMCORE Corporation

EMKR provides compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite, and terrestrial solar power markets. EMKR is the world’s largest manufacturer of highly efficient radiation hard solar cells for space power applications.

** EMKR has been awarded a contract by Dutch Space of Leiden, The Netherlands to manufacture, test, and deliver the solar panels to power the Cygnus’ spacecraft being developed by Orbital Sciences Corporation for NASA’s Commercial Resupply Service project.

The total value of the contract would be in excess of $15 million.

More about EMKR

...

BioElectronics Corp. is focused on producing inexpensive, drug–free, anti-inflammatory medical devices and patches. The company’s wafer thin patches contain an embedded microchip and battery that deliver pulsed electromagnetic energy. BioElectronics markets and sells its products under the brand names ActiPatch™ and RecoveryRx™.

The dermal patch delivery system has created numerous new product opportunities for treating chronic and acute inflammatory conditions. The market potential is estimated at $10 billion, or 400 million incidents, worldwide. The value proposition of BioElectronics’ ActiPatch is the delivery of drug-free therapy that reduces pain and inflammation, while accelerating healing by 30% to 50%.

The company’s products have broad regulatory market clearance in many international countries for the relief of pain, swelling, and accelerated healing. BioElectronics’ strategy is to identify one strong distributor in a given country and give this distributor country-wide distribution rights in return for minimum yearly quotas. To date the Company has signed agreements with

...

Imaging3 Inc. is a leading provider of advanced technology medical imaging devices. Founded in 1993 by Dean Janes, the Company has developed a breakthrough medical imaging device. This device produces 3D medical diagnostic images of virtually any part of the human body in real-time. Imaging3 Inc. trades on the OTC Bulletin Board. They have their headquarters in Burbank, California.

The 3D images, instantly constructed in real-time, are useable for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Healthcare workers using Imaging3 devices will be able to instantly view 3D, high-resolution images. The Company intends to use their existing base of operations and channels of distribution to launch their new medical imaging devices business, based on this Imaging3 Technology.

The Dominion Volumetric Imaging Scanner (DVIS) is a patented mobile fluoroscopy technology. This product can produce a

...